Study of ABSK-011 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This early-phase study tests how safe ABSK-011 is, what side effects it causes, and how the body processes the drug. It may help certain patients with advanced solid cancers (including some liver cancer cases) whose tumors have specific test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old (or within the local allowed range).
- Your cancer is advanced and has either gotten worse after standard treatment, you could not tolerate standard treatment, or there is no standard option.
- You can have the study only if your health status is good enough: ECOG 0 to 1 and expected life span is at least 3 months.
- You must be able to provide fresh or stored biopsy tissue for a lab test for FGF19 overexpression (for the HCC groups).
- Your blood counts and organ tests must be adequate (like white blood cells, platelets, liver and kidney function) within 14 days before starting.
- For women who could become pregnant (and non-sterilized men/women of childbearing potential), you must use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ABSK-011, combined with standard care, against a placebo with standard care for people with advanced liver cancer that has a specific marker called FGF19 overexpression. The goal is to see if ABSK-011 can help slow the disease.
This Phase 2 study tests ABSK-011 combined with either atezolizumab or the usual care in people with advanced or unresectable liver cancer. It aims to see if the treatment helps shrink tumors and control the cancer when standard options aren’t working or can’t be used.
This trial tests two new targeted drugs (ABSK-011 and ABSK043) for people with advanced liver cancer whose tumors have high levels of the FGF19 protein and who have already tried at least one other treatment.
This trial tests a new drug called ABSK112 for people with advanced non-small cell lung cancer, especially those whose cancer has a specific change in the EGFR gene (exon 20 insertion). The main goals are to see if it's safe and how the body handles it.
This trial tests a new drug called ABSK131 in people whose cancer has a missing MTAP gene. It is for advanced solid tumors that have not responded to standard treatments.
This trial tests a new drug called ABSK211 in people with advanced solid tumors that have a change in the KRAS gene. The goal is to see if the drug is safe and works against the cancer.
Hear when a new Advanced Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.